Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2007-09-24
2010-11-02
Zeman, Robert A (Department: 1645)
Chemistry: molecular biology and microbiology
Vector, per se
C536S023100, C536S023700
Reexamination Certificate
active
07824908
ABSTRACT:
The present invention relates to a genetically engineered P30 antigen and a combination or mixture of antigens (e.g., the genetically engineered P30 antigen and P35) that may be used in the detection of IgM and/or IgG antibodies toToxoplasma gondii. Furthermore, the present invention also relates to methods of using this genetically engineered P30 antigen and combination of antigens, antibodies raised against this genetically engineered P30 antigen and combination of antigens, as well as kits and vaccines containing the genetically engineered P30 antigen and antigens present in the combination.
REFERENCES:
patent: 4582788 (1986-04-01), Erlich
patent: 4683194 (1987-07-01), Saiki et al.
patent: 4683202 (1987-07-01), Mullis
patent: 5231020 (1993-07-01), Jorgensen
patent: 5643758 (1997-07-01), Guan et al.
patent: 5912120 (1999-06-01), Goldstein et al.
patent: 6183952 (2001-02-01), Billing-Medel et al.
patent: 6329157 (2001-12-01), Maine et al.
patent: 6372443 (2002-04-01), Jacobs et al.
patent: 6395472 (2002-05-01), Leary et al.
patent: 7094879 (2006-08-01), Maine et al.
patent: 0050424 (1982-04-01), None
patent: 0084796 (1983-03-01), None
patent: 0201184 (1986-12-01), None
patent: 0237362 (1987-09-01), None
patent: 0237362 (1987-09-01), None
patent: 0258017 (1988-02-01), None
patent: 0751147 (1990-04-01), None
patent: 0431541 (1991-12-01), None
patent: 0201184 (2004-04-01), None
patent: 9602654 (1996-01-01), None
patent: 9961906 (1999-02-01), None
patent: 9966043 (1999-12-01), None
Stratagene Catalog (1991).
Hsu, Sheng-Chieh et al., A monoclonal antibody reacts with maltose-binding protein ofEscherichia coliand related enteric bacteria, vol. 204, No. 2,pp. 16-174, May 1997.
Riggs, Paul, Expression and Purification of Maltose-Binding Protein Fusions, vol. Chapter 16, p. Unit 16.6, May 2001.
Altschul, Stephen et al., Nucleic Acids Research, vol. 25, No. 17,p. 3389-3402, 1997.
Bonhomme, Annie et al, The Journal of Histochemistry & Cytochemistry, vol. 46(12), 1998, pp. 1411-1421.
Burg, J. Lawrence et al., The Journal of Immunology, vol. 141, No. 10, 1988, pp. 3584-3591.
Cesbron-Delauw, M.F. et al., PNAS, vol. 86, 1989, pp. 7537-7541.
Desmonts, Georges et al., Journal of Clinical Microbiology, vol. 11, No. 6, pp. 562-568, 1986.
Gerhold, et al., BioEssays, vol. 18, No. 12, (1996), pp. 973-981.
He, Xiao-Lin, et al., Nature Structural Biology, vol. 9, No. 8, 2002, pp. 606-611.
Higgins, et al., Cabios, (1989) 5L151-153.
Huskinson, Jayne et al., Journal of Clinical Microbiology, vol. 28, No. 12, 1990, pp. 2632-2636.
Jacobs, Leon et al., The Journal of Parasitology, 1956, pp. 308-314.
Johnson, Alan M. et al., Dept. of Micro. and Infectious Diseases, vol. 99, 1991, pp. 127-132.
Kapust, Rachel et al., Protein Science, vol. 8, 1999, pp. 1668-1674.
Kataoka, Kunishhige et al., Biochem. and Biophys. Research Commun., vol. 250, pp. 409-413, 1998.
Kim, Kami et al., Infection and Immunity, vol. 62, No. 1, 1994, pp. 203-209.
Mevelec, Marie-Noelle et al., Mol. and Biochem Parasit., vol. 56, (1992), pp. 227-238.
Mullis, K. et al., Cold Spring Harbor Laboratory, (1986), pp. 263-273.
Nam, Ho-Woo et al., The Korean Journal of Parasitology, vol. 34, No. 2, (1996), pp. 135-141.
Naot, Yehudith et al., The Journal of Infectious Diseases, vol. 142., No. 5, (1980), pp. 757-766.
Needleman, Saul B. et al., J. Mol. Biol. vol. 48, (1970), pp. 443-453.
New England Biolabs, Inc., 1998/99 Catalog, pp. 136-137.
Pearson, William et al, PNAS, vol. 85, (1988), pp. 2444-2448.
Pouletty, Ph. et al, Elsevier Science Publishers, (1984), pp. 289-298.
Prytulla, Stefan et al., FEBS Letters, vol. 399, (1996), pp. 283-289.
Prince, Jeffrey B. et al., Mol. and Bio. Parsit., vol. 34, (1989), pp. 3-13.
Prince, Jeffrey B. et al., Mol. and Bio. Parsit.,vol. 43, (1990), pp. 97-106.
Remington, Jack S., et al., Infectious Diseases of the Fetus & Newborn Infant, 4th Ed. Saunders Company, “Toxoplasmosis”, J.S. Remington and J.O. Klein, Eds., pp. 140-267, Saunders, Philadelphia, Pennsylvania (1995).
Robinson, John M. et al., J. Of Clinical Micro.,vol. 31, No. 3, (1993), pp. 629-635.
Russell, Robert B., et al, J. Mol. Biol., vol. 244, (1904), pp. 332-350.
Sabin, Albert B. et al., Science, vol. 108, (1948), pp. 660-663.
Saavedra, Rafael, et al., The Journal of Immunology, vol. 147, No. 6 (1991), pp. 1975-1985.
Sambrook, J., et al., Molecular Cloning, Cold Spring Harbor Laboratory Press, (1989), Cover and table of contents.
Safford, et al., J. Clin. Pathol., Automated Microparticle Enzyme Immunoassays for IgG and IgM Antibodies to Toxoplasma Gondii, vol. 44, (1991), pp. 238-242.
Smith, Advances in Applied Mathematics, vol. 2, (1981), pp. 482-489.
Velge-Roussel, F. et al., Mol. and Biochemical Parasitology, vol. 66, (1994), pp. 31-38.
Walton, Bryce C. et al., American Journal of Tropical Medicine and Hygiene, vol. 15, No. 2, pp. 149-152, 1966.
Wells, Timothy N. C. et al., Journal of Meukocyte Biol., vol. 61, (1997), pp. 545-550.
Withers-Martinez, Chrislaine et al., Protein Engineering, vol. 12, No. 12, (1999), pp. 1113-1120.
Zweig, Mark H. et al., Clin. Chem., vol. 39, No. 4, (1993), pp. 561-577.
Bliese Timothy R.
Ginsburg Sanford R.
Maine Gregory T.
Patel Chandu B.
Becker Cheryl L.
Zeman Robert A
LandOfFree
Genetically engineered P30 antigen, improved antigen... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Genetically engineered P30 antigen, improved antigen..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genetically engineered P30 antigen, improved antigen... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4194424